![Fred van Leuven](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fred van Leuven
Corporate Officer/Principal presso
Katholieke Universiteit Leuven
Profilo
Fred van Leuven is the founder of AC Immune SA, founded in 2003, and reMYND NV, founded in 2002.
Dr. van Leuven currently holds the position of Professor at Katholieke Universiteit Leuven.
Dr. van Leuven earned a doctorate degree from Ghent University in 1976 and a graduate degree from Ghent University in 1970.
Posizioni attive di Fred van Leuven
| Società | Posizione | Inizio |
|---|---|---|
Katholieke Universiteit Leuven
 Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Precedenti posizioni note di Fred van Leuven
| Società | Posizione | Fine |
|---|---|---|
| AC IMMUNE SA | Fondatore | - |
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services Engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders | Fondatore | - |
Formazione di Fred van Leuven
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
53
Relazioni di 1° grado
4
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
AC Immune SA
 AC Immune SA Pharmaceuticals: MajorHealth Technology Manufactures precision medicines for neurodegenerative diseases | Health Technology |
Ghent University
 Ghent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Katholieke Universiteit Leuven
Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services Engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders | Commercial Services |
